Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : establishes new Sustainability Committee of the Board (Form 6-K)

09/23/2021 | 06:52am EDT
AstraZeneca establishes new Sustainability Committee of the Board
AstraZeneca PLC announced today that the Board has established a Sustainability Committee. The Committee has been constituted to monitor the execution of the Company's sustainability strategy, to oversee the communication of the Company's sustainability activities with its stakeholders and to provide input to the Board and other Board Committees on sustainability matters. The terms of reference of the Committee are available at www.astrazeneca.com/content/dam/az/Investor_Relations/corporate-governance/AZ_Sustainability_Committee_ToRs.pdf.
The members of the Committee, all of whom are Non-Executive Directors of the Company, are Nazneen Rahman (Chairman of the Committee), Sheri McCoy, Andreas Rummelt and Marcus Wallenberg. These appointments take effect and the Committee will operate from 1 October 2021.
The establishment of a Sustainability Committee is a natural evolution of the Company's previous governance arrangement of having a single Board member with responsibility for overseeing sustainability matters on behalf of the Board.
Further information about sustainability at AstraZeneca is available at www.astrazeneca.com/sustainability.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC


AstraZeneca plc published this content on 23 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 September 2021 10:51:03 UTC.

ę Publicnow 2021
All news about ASTRAZENECA PLC
02:17pASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
10:21aWALL STREET STOCK EXCHANGE : 84% of Q3 earnings reports exceed expectations
08:11aANALYST RECOMMENDATIONS : American Express, Beyond Meat, Microsoft, Oracle, Weibo...
07:39aUNIVERSITY OF BIRMINGHAM : A third of leukaemia patients do not generate any antibody resp..
07:27aASTRAZENECA : Imfinzi plus chemotherapy significantly improved overall survival in 1st-lin..
07:09aASTRAZENECA : JP Morgan reiterates its Buy rating
06:14aASTRAZENECA : Imfinzi plus chemotherapy significantly improved overall survival in 1st-lin..
03:46aASTRAZENECA : S.Korea to donate 1 mln doses of AstraZeneca's vaccine to Iran -KDCA
02:31aMedivir Appoints Jens Lindberg as Chief Executive Officer
02:17aASTRAZENECA : Imfinzi Improves Survival in Biliary Tract Cancer Patients
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 441 M - -
Net income 2021 4 862 M - -
Net Debt 2021 24 847 M - -
P/E ratio 2021 25,9x
Yield 2021 3,15%
Capitalization 139 B 191 B -
EV / Sales 2021 4,61x
EV / Sales 2022 3,70x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 89,42 $
Average target price 137,82 $
Spread / Average Target 54,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.83%191 835
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985